Home › NDC Lookup › Ingredients › Fluphenazine Hydrochloride › 59651-0689-01
⚪image loading
(from DailyMed)

Fluphenazine Hydrochloride 10 mg Tablet, 100-count — NDC 59651-689-01 (Billing 59651-0689-01)

by Aurobindo Pharma Limited · 100 TABLET in 1 BOTTLE

This is a package of 100 tablets of Fluphenazine Hydrochloride 10 mg Tablet from Aurobindo Pharma Limited, marketed since Aug 2023 and currently FDA-listed; retail pharmacies pay about $0.4309 per tablet (NADAC). It is the main listing for this product, which comes in 3 package sizes.

NDC 59651-0689-01
🏷️ FDA NDC (as labeled) 59651-689-01 billing pads the product segment with a zero
This package
Contains100-count Cost per ea$0.4309 NADAC Per package$43.09 / 100 tablets Pack sizes3 compare ↓
Also priced by: Medicaid pays $0.8155/unit · Part D plans $0.5833/unit — full pricing hub ↓
Main listing for product 59651-689 · Also comes in: 500 tablets 59651-689-05 30000 tablets 59651-689-62
On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Oct 1, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

⚠️
Other active recalls for Fluphenazine Hydrochloride (different manufacturers) — 3 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class III · Aug 25, 2026 — Failed impurities/degradation specifications: (OOS) for Organic Impurities by HPLC (Impurity-A) during testing at the 18 months long term stability. Result: 1.1 percent. Spec: 1.0 percent. (Ajanta Pharma USA Inc) · FDA recall D-0836-2026
Class II · Mar 13, 2025 — CGMP Deviations (Glenmark Pharmaceuticals Inc., USA) · FDA recall D-0326-2025
Class II · Mar 13, 2025 — CGMP Deviations (Glenmark Pharmaceuticals Inc., USA) · FDA recall D-0327-2025
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 59651-689-01
Product NDC 59651-689
11-digit billing NDC 59651068901
NCPDP billing unit EA — each (per item)
SPL Set ID 3989e88e-b12f-46ca-8f32-0b095a98d068
DEA schedule Non-controlled
Marketing category DRUG FOR FURTHER PROCESSING
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2023-08-18
Dosage form TABLET
Substance FLUPHENAZINE HYDROCHLORIDE

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 59200025100320
GCN Seq No 003824
GCN 14603
HICL code 001626
Ingredient (HICL) Fluphenazine Hcl
HIC1 code H
Therapeutic class — broad (HIC1) Nervous System (Except Autonomic)
HIC2 code H2
Therapeutic class — intermediate (HIC2) Psychoactive Drugs
HIC3 code H2G
Therapeutic class — specific (HIC3) Antipsychotics,Phenothiazines
AHFS code 28:16.08.24
AHFS class Phenothiazines
FDB label name FLUPHENAZINE 10 MG TABLET
FDB brand name Fluphenazine Hcl
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 003824
  • GCN: 14603
  • GPI-14 (Medi-Span): 59200025100320
  • HICL (First Databank): 001626
  • AHFS class code: 28:16.08.24
Why two NDCs? The FDA registers this code as 59651-689-01 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 59651-0689-01. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

Clinical

Label name FLUPHENAZINE 10 MG TABLET Ingredient Fluphenazine Hcl
📖 What it is MedlinePlus · NLM

Fluphenazine is an antipsychotic medication used to treat schizophrenia and psychotic symptoms such as hallucinations, delusions, and hostility. Fluphenazine is in a class of medications called antipsychotics. It works by changing the activity of certain natural substances in the brain.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • Fluphenazine is an antipsychotic medication used to manage psychotic disorders — most commonly schizophrenia. It's available as tablets, an oral liquid, and injections. The long-ac...
  • Fluphenazine Decanoate Injection is chemically designed to release slowly after a single shot, so one injection can keep working for up to four weeks or even longer. The regular ta...
  • How is the long-acting injection different from the tablets or regular shot?
  • The most common side effects involve movement — things like muscle stiffness, a restless, fidgety feeling, or tremors. These can often be managed by adjusting your dose or adding a...
📖 Read our full Fluphenazine guide →

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $0.431 $43.09 / 100 tablets
Medicaid paysCMS SDUD · 12 mo $0.8155 $81.55 / 100 tablets
Medicare drug plans payPart D · Q2 2026 $0.5833 $58.33 / 100 tablets
NADAC price history (per ea) — tap or hover for the price & month
Dec 2025 Mar 2026 Jun 2026 Sep 2026 $0.461 $0.380
▼ Down 6% over the last 10 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
59651-0689-01 You're viewing this Main listing 100 TABLET in 1 BOTTLE $0.4309 / ea $43.09 2023-08-18 — Active
59651-0689-05 59651-689-05 500 TABLET in 1 BOTTLE — — 2023-08-18 — Active
59651-0689-62 59651-689-62 30000 TABLET in 1 BAG — — — — Active

You're viewing the smallest of 3 pack sizes for this product.

In Medicaid, this is the most-dispensed pack of this product — about 100% of fills over the last four reported quarters. See all packs ↓

Pack size FAQ

What quantity is in this package?
This is a 100-count package — 100 tablet in 1 bottle.
How does this package differ from NDC 59651-0689-05?
Both are Fluphenazine Hydrochloride 10 mg Tablet — the drug itself is identical. This page's package is the 100-count one, while NDC 59651-0689-05 is the 500 tablets package.
What NDC number is used to bill for this package of Fluphenazine Hydrochloride 10 mg Tablet?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Fluphenazine Hydrochloride 10 mg 00527-1791-01 Lannett 100 tablets $0.431 AB Availability likely —
Fluphenazine Hydrochloride 10 mg 00832-6006-11 Upsher-Smith 100 tablets $0.431 AB Availability likely —
Fluphenazine Hydrochloride 10 mg 00904-7160-61 Major 1 tablet $0.431 AB Availability likely —
Fluphenazine Hydrochoride 10 mg 16571-0892-09 Rising 90 tablets $0.431 AB Availability likely —
Fluphenazine Hydrochloride 10 mg 24979-0139-01 Upsher-Smith 100 tablets $0.431 — Availability likely —
Fluphenazine hydrochloride 10 mg 27241-0252-01 Ajanta 100 tablets $0.431 AB Availability likely —
Fluphenazine Hydrochloride 10 mg 31722-0387-01 Camber 100 tablets $0.431 AB Availability likely —
Fluphenazine Hydrochloride 10 mg 43598-0037-01 Dr. 100 tablets $0.431 AB Availability likely —
Fluphenazine Hydrochloride 10 mg 50268-0369-15 AvPAK 1 tablet $0.431 AB Availability likely —
Fluphenazine Hydrochloride 10 mg 51672-4236-01 Sun 100 tablets $0.431 AB Availability likely —
Fluphenazine Hydrochloride 10 mgthis 59651-0689-01 Aurobindo 100 tablets $0.431 — Availability likely —
Fluphenazine Hydrochloride 10 mg 60687-0761-01 American 1 tablet $0.431 AB Availability likely —
fluphenazine hydrochloride 10 mg 62135-0419-90 Chartwell 90 tablets $0.431 AB Availability likely —
Fluphenazine Hydrochloride 10 mg 62332-0791-31 Alembic 100 tablets $0.431 AB Availability likely —
Fluphenazine Hydrochloride 10 mg 68462-0338-01 Glenmark 100 tablets $0.431 AB Availability likely —
fluphenazine hydrochloride 10 mg 69238-1681-01 Amneal 100 tablets $0.431 AB Availability likely —
Fluphenazine Hydrochloride 10 mg 70710-1491-01 Zydus 100 tablets $0.431 AB Availability likely —
Fluphenazine Hydrochloride 10 mg 70954-0276-10 ANI 100 tablets $0.431 AB Availability likely —
Fluphenazine Hydrochloride 10 mg 90096-0124-01 Zameer 100 tablets $0.498 AB FDA listed +16%
Fluphenazine Hydrochloride 10 mg 10135-0728-01 Marlex 100 tablets — AB FDA listed —
Fluphenazine Hydrochloride 10 mg 46708-0791-31 Alembic 100 tablets — AB FDA listed —
Fluphenazine Hydrochloride 10 mg 51407-0461-01 Golden 100 tablets — AB FDA listed —
Fluphenazine Hydrochloride 10 mg 70518-4673-00 REMEDYREPACK 1 tablet — AB FDA listed —
Fluphenazine Hydrochloride 10 mg 70771-1584-01 Zydus 100 tablets — AB FDA listed —
Fluphenazine Hydrochloride 10 mg 71205-0840-00 Proficient 100 tablets — — FDA listed —
Fluphenazine Hydrochloride 10 mg 72205-0115-05 Novadoz 500 tablets — AB FDA listed —
Fluphenazine Hydrochoride 10 mg 70518-4691-00 REMEDYREPACK 1 tablet — AB FDA listed —
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2023
On the market since
Aug 2023
📍
2026
Currently FDA-listed
3 years listed
🔓
·
Generic versions listed
see equivalents
✅Generic appears available

FDA-approved generic versions are listed, and recent pricing/market data suggests they may be available — see Therapeutic equivalents.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerAurobindo Pharma Limited
Labeler code59651
First marketedAug 2023
Product typeDrug For Further Processing
Portfolio1,456 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full FDA label FDA SPL

The complete FDA label for this product, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
📄 FDA label
📄 FDA label 19 words ▾

No FDA label is on file for this product yet. Labels load from openFDA / DailyMed and refresh weekly.

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
785
Units reimbursed last 4 qtrs
35.7K
Gross reimbursed last 4 qtrs
$29.1K
Avg / prescription
$37.06
Avg / unit
$0.8155
Latest quarter Q1 2026
66Rx
Medicaid pays / ea
$0.8155
gross reimbursed
vs
NADAC / ea
$0.4309
acquisition cost
=
Spread
+$0.3846
+89% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
54% FFS 46% MCO
Fee-for-service · 422 Rx Managed care · 363 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: no data reported WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: 635 units · 11.1 per 100k residents MN Wisconsin: no data reported WI Michigan: 1,576 units · 15.7 per 100k residents MI New York: 3,855 units · 19.7 per 100k residents NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: no data reported OR Nevada: 13,368 units · 419 per 100k residents NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: 1,793 units · 14.3 per 100k residents IL Indiana: no data reported IN Ohio: 1,143 units · 9.7 per 100k residents OH Pennsylvania: no data reported PA New Jersey: 2,000 units · 21.5 per 100k residents NJ Massachusetts: no data reported MA California: 5,845 units · 15.0 per 100k residents CA Utah: no data reported UT Colorado: no data reported CO Nebraska: no data reported NE Missouri: 1,782 units · 28.8 per 100k residents MO Kentucky: no data reported KY West Virginia: no data reported WV Virginia: no data reported VA Maryland: no data reported MD Connecticut: no data reported CT Rhode Island: no data reported RI Arizona: no data reported AZ New Mexico: no data reported NM Kansas: no data reported KS Arkansas: no data reported AR Tennessee: no data reported TN North Carolina: 808 units · 7.5 per 100k residents NC South Carolina: no data reported SC Delaware: no data reported DE Oklahoma: no data reported OK Louisiana: 1,768 units · 38.7 per 100k residents LA Mississippi: no data reported MS Alabama: no data reported AL Georgia: no data reported GA D.C.: no data reported DC Hawaii: no data reported HI Texas: no data reported TX Florida: 1,102 units · 4.9 per 100k residents FL
Units reimbursed · per 100k residents
4.9419
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Nevada 419 /100k
2 Louisiana 38.7 /100k
3 Missouri 28.8 /100k
4 New Jersey 21.5 /100k
5 New York 19.7 /100k
6 Michigan 15.7 /100k
7 California 15.0 /100k
8 Illinois 14.3 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
100 tablets this page59651-0689-01 785 Rx · $29,094
500 tablets59651-0689-05 No Medicaid data
30000 tablets59651-0689-62 No Medicaid data
Drug total (last 4 qtrs): 785 Rx · 35,675 units · $29,094 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

About this NDC listing & data coverage

Listed for further processing / repackaging

What "drug for further processing" means

FDA lists this package under the "drug for further processing" marketing category: Aurobindo Pharma Limited supplies it to other companies for further processing or repackaging (blister cards that are later repackaged or co-packaged are a common example). The units themselves are a finished dosage form — which is why pricing or Medicaid data can still appear — but this exact package code may not be the presentation a retail pharmacy dispenses.

What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos — Not published for this NDC No photo available yet for this listing.
Inactive ingredients (structured) — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available.
NADAC pharmacy acquisition price (CMS) ✓ Available
Orange Book / therapeutic-equivalence data — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope.
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) ✓ Available
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Is this NDC FDA-approved?
An NDC listing does not by itself establish FDA approval — the NDC Directory records that a product is listed with FDA, not that it was reviewed and approved. This listing's marketing category is "Drug For Further Processing". Products approved under an application carry an NDA, ANDA, or BLA number.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by Aurobindo Pharma Limited. Listing status can change — the directory data on this page refreshes weekly.
Does this product come in other package sizes?
Yes — the FDA directory lists 2 other package presentations of this same product, including 500 tablets (59651-0689-05), 30000 tablets (59651-0689-62). Each has its own NDC and its own page — see the package list near the top of this page.
Who lists this product with the FDA?
Aurobindo Pharma Limited is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
← 59651-0688-01 · Aurobindo 59651-0691-01 · Aurobindo →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.